Invention Grant
- Patent Title: Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
-
Application No.: US16344459Application Date: 2017-10-27
-
Publication No.: US10781215B2Publication Date: 2020-09-22
- Inventor: Stephen T. Wrobleski , David S. Weinstein , Michael G. Yang
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- International Application: PCT/US2017/058645 WO 20171027
- International Announcement: WO2018/081488 WO 20180503
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D471/04 ; C07D473/34
Abstract:
Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
Public/Granted literature
- US20190322672A1 HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES Public/Granted day:2019-10-24
Information query
